While the data was amassing, suddenly there came a tapping,
As of something gently rapping, rapping at LIGO’s door.

The source of a mysterious glitch in data from a gravitational wave detector has been unmasked: rap-tap-tapping ravens with a thirst for shaved ice. At the Advanced Laser Interferometer Gravitational-Wave Observatory, or LIGO, in the desert of Hanford, Wash., scientists noticed a signal that didn’t look like gravitational waves, physicist Beverly Berger said on April 16 at a meeting of the American Physical Society.

A microphone sensor that monitors LIGO’s surroundings caught the sounds of pecking birds on tape in July 2017, Berger, of the LIGO Laboratory at Caltech, said. So the crew went out to the end of one of the detector’s 4-kilometer-long arms to check for evidence of the ebony birds at the scene.

Sure enough, frost covering a pipe connected to the cooling system was covered in telltale peck marks from the thirsty birds. One raven, presumably seeking relief from the desert heat, was caught in the act. Altering the setup to prevent ice buildup now keeps the ravens from tapping, evermore.

After a two-day delay, the planet-hunting TESS telescope successfully launched into a clear blue sky at Cape Canaveral, Fla., at 6:51 p.m. EDT on April 18.

TESS, the Transiting Exoplanet Survey Satellite, is headed to an orbit between the Earth and the moon, a journey that will take about two months. In its first two years, the telescope will seek planets orbiting 200,000 nearby, bright stars, and identify the best planets for further study. TESS’ cameras will survey 85 percent of the sky by splitting it up into 26 zones and focusing on each zone for 27 days apiece.

TESS launched on a SpaceX Falcon 9 rocket. A previous launch attempt on April 16 was scrubbed so that SpaceX could run more tests on the rocket’s guidance, navigation and control system. SpaceX recovered the rocket’s first stage booster on an autonomous drone ship and hopes to reuse the rocket on a future launch.

Quantum entanglement has left the realm of the utterly minuscule, and crossed over to the just plain small. Two teams of researchers report that they have generated ethereal quantum linkages, or entanglement, between pairs of jiggling objects visible with a magnifying glass or even the naked eye — if you have keen vision.

Physicist Mika Sillanpää and colleagues entangled the motion of two vibrating aluminum sheets, each 15 micrometers in diameter — a few times the thickness of spider silk. And physicist Sungkun Hong and colleagues performed a similar feat with 15-micrometer-long beams made of silicon, which expand and contract in width in a section of the beam. Both teams report their results in the April 26 Nature.
“It’s a first demonstration of entanglement over these artificial mechanical systems,” says Hong, of the University of Vienna. Previously, scientists had entangled vibrations in two diamonds that were macroscopic, meaning they were visible (or nearly visible) to the naked eye. But this is the first time entanglement has been seen in macroscopic structures constructed by humans, which can be designed to meet particular technological requirements.

Entanglement is a strange feature of quantum mechanics, through which two objects’ properties become intertwined. Measuring the properties of one object immediately reveals the state of the other, even though the duo may be separated by a large distance (SN: 8/5/17, p. 14).

Quantum mechanics’ weird rules typically apply to small fry — atoms, electrons and other tiny particles — and not to larger things such as cats, chairs or buildings. But that division leads to a confounding puzzle. “Atoms behave like atoms, and cats behave like cats, and so where is that transition in between?” says physicist Ben Sussman of the National Research Council of Canada in Ottawa, who was not involved in the research.

Now, scientists are extending the dividing line to larger and larger objects. “One of our motivations is to keep on testing how far we can push quantum mechanics,” says Sillanpää, of Aalto University in Finland. “There might be some fundamental limit for how big objects can be” and still be quantum.
In Sillanpää’s experiment, two tiny aluminum sheets — consisting of about a trillion atoms and just barely visible with the naked eye — vibrate like drumheads and interact with microwaves bouncing back and forth in a cavity. Those microwaves play the role of drum major, causing the two drumheads to sync up their motions. In many previous demonstrations of entanglement, the delicate quantum link is transient. But this one was long-lived, persisting as long as half an hour in experiments, Sillanpää says, and, in theory, even longer. “Our entanglement lasts forever, basically.”
Taking a different tactic, Hong and colleagues demonstrated entanglement with two silicon beams, big enough to be seen with a magnifying glass. Within a region of each beam, in a 1-micrometer-long section composed of about 10 billion atoms, the structure expanded and contracted — as if taking deep breaths in and out — in response to being hit with light. Instead of microwaves, Hong and colleagues’ work used infrared light of the wavelength typically transmitted in telecommunications networks made of optical fibers, which means it could be incorporated into a future quantum internet. “From a technology standpoint, that really is crucial,” says physicist John Teufel of the National Institute of Standards and Technology in Boulder, Colo., who was not involved with the work.

Scientists could use such vibrating structures within a quantum network to convert quantum information from one type to another, transitioning from particles of light to vibrations, for example. Once constructed, a quantum internet could allow quantum computers to communicate and provide unhackable communication across the globe (SN: 10/15/16, p. 13).

The ability to entangle these specially designed structures moves scientists a step closer to that vision. “You can really start to think about building real devices with these things,” Sussman says.

New insights into how stars like the sun die might help explain why astronomers find bright planetary nebulae where they’re least expected. Simulations of how these stellar remnants form suggest that smaller stars have cores that heat up fast enough to produce bright nebulae upon their demise, researchers report online May 7 in Nature Astronomy.

A planetary nebula is what’s left over when a sunlike star sheds its outer envelope of gas. Radiation from the stellar core, now exposed, sets the expanding shell of gas aglow, creating the kind of candy-colored clouds seen in spectacular Hubble Space Telescope images, like that of the Cat’s Eye Nebula and the butterfly-shaped NGC 6302 (SN Online: 9/5/13).
Astronomers had thought a star’s mass dictated what sort of nebula it produced, with more massive stars creating the brightest nebulae and stars with lower masses, like the sun, making nebulae too faint to see from another galaxy.

But that idea didn’t match observations: The brightest planetary nebulae in older elliptical galaxies — thought to be home to only low-mass stars — are just as luminous as those in younger, spiral galaxies, where massive stars abound. The puzzle vexed astronomers for decades.

Now, astrophysicist Albert Zijlstra at the University of Manchester in England, and colleagues have simulated planetary nebulae formation based on a new theory of stellar evolution. This theory says that after smaller stars shed their outer envelopes, their bare cores heat up more quickly than previously thought. That allows the cinderlike stellar core to pump more energetic radiation into the surrounding nebula before the gas expands too far out into space, ultimately making for a brighter nebula, explains Christophe Morisset, an astronomer at the National Autonomous University of Mexico in Mexico City not involved in the work.

Simulations showed that stars ranging from 1.1 to three times the mass of the sun produce nebulae with similar brightness. That result could explain why nebulae found in galaxies with stars that are 7 billion years old can be just as bright as those found in galaxies chock-full of 1-billion-year-old stars.
This finding marks “an important step forward” in understanding the universe’s population of planetary nebulae, says Penn State astronomer Robin Ciardullo, who was not involved in the work.

But some mystery still remains: For the most ancient elliptical galaxies with very small stars over 7 billion years old, the simulations didn’t produce planetary nebulae bright enough to match what astronomers see in the sky. So there’s still “a little ways to go” before astronomers can explain why bright nebulae are so ubiquitous, he says.

Going green may mean staying at home.

Global tourism contributes about 8 percent of total greenhouse gas emissions to the atmosphere, researchers report May 7 in Nature Climate Change. That carbon footprint is about three times as large as tourism-related emissions estimated by previous studies.

The jump is largely because the new study doesn’t just tally up emissions from the traveling itself, like hopping a flight, going on a road trip or taking a cruise. It also looks at the impact of the goods and services that tourists enjoy, from food to shopping to hotel stays.
Who has the biggest carbon footprint? The United States topped the list, as both a top destination for tourists and a source of tourists. Other prosperous nations, such as Canada and Germany, also have a big footprint, and increasingly wealthy nations, such as China and Mexico, are catching up in this amazing race.

Take a look at global tourism by the numbers:

4.5 gigatons
The amount of carbon dioxide and other greenhouse gases that came from tourism in 2013.

2.7 percent
The share of the global total of emissions that comes just from Canadians and Mexicans traveling to the United States for tourism.

300 kilograms
Increase, from 2009 to 2013, in the yearly carbon footprint for each inhabitant of the tiny island nation of the Maldives as a result of international tourism.

$4.7 trillion
The amount of money, in U.S. dollars, spent on global tourism in 2013. That’s up from $2.5 trillion in 2009.

3 percent
Current annual growth in money spent on global tourism, which translates to tourism-related emissions of 6.5 gigatons of carbon dioxide and other greenhouse gases by 2025.

It’s vacation season — time for swimming pools, hot tubs and water parks. But you might want to think twice before getting wet, says a new report from the U.S. Centers for Disease Control and Prevention.

From 2000 to 2014, public health officials from 46 states and Puerto Rico reported 493 outbreaks associated with treated recreational water, resulting in more than 27,000 illnesses and eight deaths, according to a report in the May 18 Morbidity and Mortality Weekly Report. Hotel pools and hot tubs were the setting for about a third (32 percent) of the outbreaks, followed by public parks (23 percent), club/recreational facilities (14 percent) and water parks (11 percent).

Most of the infections were from three organisms that can survive chlorine and other commonly used disinfectants: Cryptosporidium, a parasite that can cause gastrointestinal problems; Pseudomonas, a bacteria that causes swimmer’s ear; and Legionella, a bacteria that causes a pneumonia-like illness.

So, what to do? The CDC recommends a few steps before diving in: Don’t swallow pool water. Don’t let children with diarrhea in the water. And use test strips to measure levels of pH, bromine and chlorine in the water. The cleaner the water, the safer to swim.

When severe, chronic diarrhea strikes, sometimes the only cure is … more feces. It might seem bizarre, but a transplant of healthy human stool and its bacterial ecosystem can mean freedom from a painful, life-threatening illness.

The transplants — called fecal microbiota transplants, or FMTs — are becoming more and more popular. So popular that the stool bank OpenBiome has supplied more than 30,000 stool samples to clinicians and scientists since 2012. Right now, though, the government isn’t quite sure how to regulate fecal transplants. That uncertainty comes from what seems like a simple question: What is poop? Is it a drug? Is it a bodily tissue? Is it a little of both? Then, is the transplant itself a procedure? That’s a whole other regulatory category.

Out of concern that regulations would cut out desperate patients or send companies running to more profitable enterprises, some FMTs aren’t actually regulated at all. That leads to the potential for unscreened and potentially dangerous fecal samples to flood the market. A group of doctors and scientists from the University of Maryland School of Medicine in Baltimore have tried to cut through the confusion with a three-track policy plan that would help keep poop transplants clean (as clean as fecal matter gets, anyway), while still allowing patients to get transplants when they need them. The scientists also hope to encourage companies to develop potentially lucrative products for future FMTs — including options that are almost feces-free.

A fecal transplant involves taking a mixture of a donor’s poop and saline (sometimes mixed with the help of a kitchen blender) and inserting it into a patient’s large intestine or far down the gut with a nasogastric tube. Companies are working on alternatives to that procedure, such as pills that deliver the same benefits with less of an “ick” factor.
Currently, FMTs have the most potential for treating Clostridium difficile infections. C. diff is a bacterium normally found in our guts and feces. But unchecked, it can take over the large intestine. The result is inflammation and chronic severe diarrhea that can last weeks or months. There are more than 450,000 estimated cases in the United States each year, and more than 29,000 deaths. Doctors can prescribe antibiotics to kick the bugs out, but in 20 percent of patients, the infection comes back again. And again.

For those patients, FMTs can be a miracle. They resolve symptoms in 85 percent of patients with recurrent C. diff infections, compared with the roughly 20 to 30 percent success rates of antibiotics.

Unfortunately, FMTs also come with a dose of danger. Feces is a mixture of our undigested waste, the beneficial microbes needed to keep our guts healthy and whatever bacteria, fungi and viruses we’ve picked up in our busy lives. So donors need to be screened for pathogens that might make a sick recipient sicker. And the poop needs to be handled carefully to avoid contamination or infection in the people who handle and receive it.

Gastroenterologist Erik von Rosenvinge of the University of Maryland School of Medicine in Baltimore has performed more than 40 FMTs. “When I first started doing these in 2013, I was having the patients identify a friend or family member, and they would bring in the stool and I would process it myself,” he says. After the first few donations, von Rosenvinge switched to using stool from the OpenBiome stool bank. It saves money and time.

For each donation, the stool bank or hospital will test the feces for pathogens. But who sets the standard to ensure that people getting treated for C. diff are receiving “clean” stool, either from their friends or from a stool bank?

Well, right now, no one.

Poop: Drug or tissue?
The first problem is to figure out what an FMT actually is, at least, in terms of how the government should regulate one. Feces is like a drug, in that the microbes in it can change how the body functions. But because of those very microbes, feces is also a living thing that differs from person to person. In fact, in some ways, poop is like biological tissue, in that it comes from the human body.

But then, the FMT itself is something like a procedure — there’s a method involved in getting one. But that procedure is also delivering a drug. Or is it transplanting a tissue? Here we go again.

“The FDA has been reticent to create a new regulatory product category,” says Jacques Ravel, who studies the microbiome and women’s health at the University of Maryland School of Medicine. “They’ve been trying to fit the stool into one of the regulated product categories, and there’s limitations every time you do, there’s pros and cons.”

In 2013, the FDA declared that FMTs counted as a drug (technically a “live biotherapeutic product”) in terms of how they would be regulated, which, von Rosenvinge notes, “means all of us are pharmaceutical factories,” pooping out “drugs” once a day on average.

But FMTs don’t have FDA approval yet, so as a drug, an FMT is considered “investigational.” Giving one to a patient would require an investigational new drug application, or IND. Those are associated with clinical trials, meaning someone who needed an FMT would probably have to get into a clinical trial to get treatment. “At that point [in 2013], I’d only done a handful, and I had to stop because I didn’t have an IND,” von Rosenvinge recalls.

The FDA’s goal was to make sure that FMTs were safe for people. But the requirements meant that most doctors could not give FMTs. At a public workshop about FMTs in 2013, scientists and physicians spoke out against the requirements. In response, the FDA noted that it would practice “enforcement discretion.” That’s government-speak for politely looking the other way while doctors treated C. diff patients outside of clinical trials.

Unfortunately, looking the other way means that FMTs — whether prepared from a donor by a doctor or purchased from a stool bank — are still completely unregulated. As FMTs gain popularity for C. diff, von Rosenvinge notes, that could lead to problems. “You don’t want someone grabbing poop out of the local [port-a-potty] and selling it. That would be horrible,” he says. “If someone’s going to be using stool to put into a human, you want to have assurances that it was properly handled, that the donor was properly screened, that we’re doing everything within reason to minimize risk of causing problems.”

The stool banks themselves aren’t pleased with the arrangement, either. “We’re all operating on a bit of uncertainty,” says Carolyn Edelstein, the executive director of OpenBiome. Right now, OpenBiome screens all of their samples by their own standards, because the government hasn’t given them any. Everyone knows that “looking the other way” could end at any time, a move that the FDA proposed in March 2016. Then, INDs would be required again, and patients could be out of luck.

Balancing regulation and access
To patients, access — cheap access — is paramount. “The big challenge at the end of the day is access to treatment, and the fact that FMT is really cheap as its performed right now,” says Ravel. “Right now there’s no true alternative, even those coming down the pipe may be able to cure [C. diff], but they’re not going to be cheap.”

But to doctors, scientists and government, access needs to be balanced with safety. “People are doing this at home, and I think that raises issues about the safety of donations,” notes Diane Hoffman, who studies health law at the University of Maryland. “Do [patients] understand the potential for contamination and disease transmission?”

The right balance might also help promote the development of new drugs for treating C. diff — ones that extract the most useful bacteria, for example, and don’t involve an enema.

To this end, Hoffman, von Rosenvinge, Ravel and colleagues worked with a large working group of scientists, lawyers, industry partners and patient advocates to come up with recommendations for regulating FMTs, which they outlined in December in Science. The result is a slim, three-track system.

Individual FMTs for C. diff done by doctors with donors who are friends or family of the patients would be classified under “practice of medicine.” This is an exception that allows doctors to use their expertise and judgment when treating patients, as long as the treatments they’re using are legally available. No FDA approval or IND required. “We’re trusting the doctor to do what’s in the best interests of the patient,” Hoffman explains.

Stool banks, on the other hand, would be regulated like tissue banks. They’d have to comply with good manufacturing and safety practices and screen and test their donors. The banks would also have to track the patients who receive donations, and submit their long-term data to a national registry. The banks would be free to sell FMT samples, but only to treat C. diff. Any other use that the FMT hasn’t been approved for would still require a clinical trial.

The third track would be for “stool-based products.” These would be pills or delivery systems that offer, say, combinations of microbes, rather than the current practice of basically “polishing a turd,” notes von Rosenvinge. These would be regulated as biological products or drugs.

In practice, this would mean stool banks and stool transplants would be regulated more like cell and tissue banks and transplants. “Stool-based products” on the other hand, would be regulated more like drugs. No matter what, patients would have to be informed of all the risks associated with an FMT.
“I think the stand-out, excellent point of this proposed regulatory scheme is that stool banks need to be regulated, and there need to be rigorous data collection of outcomes,” says Kelly Hills, a bioethicist with Rogue Bioethics. “Track everything. The whole enchilada. We have historical precedents [such as in vitro fertilization] where we didn’t track outcomes, and 20 or 40 years down the line we’ve been kicking ourselves. It’d be nice to learn from our mistakes!”

This is especially important because while FMTs have very clear benefits for C. diff in the short term, no one really knows what the long-term effects will be. “We don’t have a lot of [long-term data] right now,” Hills notes. “We know that when you change someone’s gut microbiome you actually change a lot in their life. We have the anecdotal stories of people losing lots of weight, for example, or people’s dietary desires changing.” But the plural of anecdote isn’t data. A registry might help scientists keep track of exactly what transplants people received and their long-term effects.

But “practice of medicine” might give too much leeway to doctors to try FMT for things that they probably shouldn’t, worries Leigh Turner, a bioethicist at the University of Minnesota in Minneapolis. “‘Practice of medicine’ isn’t a curb on advertising or promotional claims,” he notes.

The group behind the policy proposal was careful not to stand in the way of further drug development. That third track was designed with the hope of promoting stool-based products, so that companies might be encouraged to pursue more of them. But if FMTs aren’t broken, why would companies — let alone patients — want to take the risks to fix them? With FMTs freely available, it might be hard to recruit patients to potential clinical trials for new drugs. “If you have a cheap solution that works and you have a patient with C. diff, that patient will not want to enter a trial with a placebo arm,” notes Ravel. After all, what if they got the placebo? They want a cure, not a game of roulette.

The policy brief isn’t policy, and the FDA hasn’t made a final call. But looking the other way isn’t going to cut it in the long term. FMTs are only used for recurrent C. diff infections right now. But scientists are interested in them for many other things. “You can get into weird science fiction areas. Would athletes start doing FMTs to try and improve their Tour de France time? Could you lose weight?” notes Hills. Some of these could be lucrative options for companies. And because FMTs are so easy to perform, people are already making headlines with the do-it-yourself route.

No matter what, a lack of regulation isn’t a long-term strategy. People are going to find other uses for feces, and the FDA will need to be prepared when they do.

Decades ago, pregnant women had to wait about 40 weeks before knowing much about their baby. But swiftly moving technology offers increasingly detailed peeks into the womb.

Beyond generating adorable 3-D ultrasounds of scrunched-up faces, researchers can now analyze a fetus’s full genome from a simple blood draw from mom. But these genome-wide prenatal tests are not ready for prime time, three medical organizations argued in a position paper in the January Prenatal Diagnosis.

The method is undoubtedly powerful. Scanning the entire genome can reveal DNA abnormalities that more limited genetic tests might miss. But scientists don’t know enough about the performance of these tests, or their pitfalls, to recommend routine use, wrote representatives from the International Society for Prenatal Diagnosis, the Perinatal Quality Foundation and the Society for Maternal-Fetal Medicine.
How to interpret the information these tests provide is not always obvious. Many genetic quirks have little or no influence on human health, and sifting through a mountain of genetic data to identify the important signals isn’t easy. So far, large studies that could reveal the utility of these tests simply haven’t been done.
Ethical and practical issues dog these whole-genome tests, too. Identifying a potentially fatal genetic abnormality can be straightforward. But often, the relationship between genetics and outcomes is less clear. Researchers are still figuring out how specific genetic changes — or more likely, combinations of many genetic changes — relate to genetically influenced disorders such as autism spectrum disorder or to a risk of dementia in the baby’s distant future. How doctors or parents should handle this murkier information is an open question.

And then there are the genetic quirks that shape traits irrelevant to health, such as future height or eye color. In a recent survey, the majority of over 1,000 obstetricians/gynecologists expressed concern about ordering genetic tests that could reveal nonmedical traits. These doctors also wondered if genetic information overload would boost parents’ anxiety, leading to unnecessary and costly treatments, researchers reported in 2016 in Prenatal Diagnosis.

That’s not to say whole-genome tests should never be used. The tests should be considered when doctors suspect a genetic abnormality that hasn’t been uncovered by other methods, the position paper notes. When this happens, it’s best to also look at the parents’ genomes to get a clearer picture of the genetic trouble. These tests ought to always come with lots of discussions between health care providers and parents, before and after testing.

A two-faced star just helped weigh an extra-massive pulsar.

The star takes about four hours to orbit its companion, a fast-spinning stellar corpse called a pulsar that’s about 10,000 light-years from Earth. That means the pair’s orbital dance is tight enough that the star always shows the same face to the pulsar, similar to how the moon is oriented to Earth.

Radiation from the pulsar has fried the near side of the companion star to a scorching 7800° Celsius, Manuel Linares of the Polytechnic University of Catalonia in Barcelona and colleagues report May 23 in the Astrophysical Journal. That’s as hot as an A-type star, which are typically around twice the mass of the sun and burn at higher temperatures. But the side facing away from the pulsar is just roughly 5400° Celsius, similar to stars like the sun.
Linares and colleagues also measured the Doppler shift — the change in the wavelength of the star’s light as it moves toward and away from the Earth — of the star’s two sides as it moved around the pulsar to calculate its orbit precisely. The team used that precision to estimate the mass of the pulsar, and found it was surprisingly heavy: around 2.3 times the mass of the sun.

A type of neutron star, pulsars are extremely dense, cramming the mass of a star into an orb the size of a planet. Previous studies of packing neutrons together at high pressures had suggested that a pulsar can’t be more massive than 2.2 solar masses without collapsing into a black hole (SN: 12/23/17, p. 7). The new finding may force a rethink of how these particles interact at high densities, Linares says.

The duo, named PSR J2215+5135, is called a “redback” binary, after the cannibalistic spider of the same name, because the pulsar is gradually stealing material from its neighbor. Eventually, the pulsar may gobble enough of the regular star to become a black hole. But at the rate the pulsar is eating, this pair seems to be stable. “They will keep dancing for a while,” Linares says.

Police are using a new type of DNA sleuthing, called genetic genealogy. Already the technique has caught murder and rape suspects in California and Washington. While solving the cases has given cause for celebration, the tactics used in catching the alleged culprits have many privacy and civil rights experts worried.

Closing the Golden State Killer case (SN Online: 4/29/18) and the previously unsolved double murder of a young Canadian couple (SN Online: 5/23/18) involved probing a public online database of people’s DNA and family-tree information called GEDmatch.
In a May 29 opinion piece published in the Annals of Internal Medicine, bioethicist Christine Grady and colleagues argue that police should be more transparent about how they use forensic DNA searches. Meanwhile, law professor Natalie Ram and colleagues go even further in an essay in the June 8 Science, writing that eroding limits on the use of crime-solving technology “threatens our collective civil liberties and opens the door to socially and politically unacceptable genetic surveillance.”

Here are a few key points in the debate:

Why are police using GEDmatch instead of DNA testing companies?
If police wanted to use 23andMe or AncestryDNA to help solve crimes, they would need a clean saliva sample from a potential suspect to send to the company for testing and analysis. But crime scene DNA doesn’t come in that form, so police can’t send DNA to the companies for testing. That’s not the case with the DNA analysis service GEDmatch, to which customers can upload raw DNA data received from testing companies.

“That means the police or law enforcement investigators are equally able, if they have enough DNA to create a sufficiently complete genetic sequence, to upload that to GEDmatch” to find potential suspects, says Ram, of the University of Baltimore School of Law.

Companies like 23andMe and Ancestry also require consent from the person the DNA belongs to before the companies will do testing. That’s, obviously, not possible with crime scene DNA. However, GEDmatch in May changed its terms of service “to explicitly embrace the use of their service by law enforcement,” Ram says.

Could these searches lead to people being investigated needlessly?
Before police tracked the Golden State Killer suspect through GEDmatch, investigators subpoenaed Family Tree DNA for information about a customer whose Y chromosome partially matched DNA from one of the crime scenes. Police then used that information to order a man in an Oregon nursing home to give a DNA sample. He was not a match.

“Just having DNA match something at the crime scene doesn’t mean the person committed the crime,” says Grady, who heads the National Institutes of Health Clinical Center’s Department of Bioethics in Bethesda, Md. “It just means that they were there, or something that they used was there.” Police still have to prove the suspect committed the crime.

If DNA tests are helping to catch criminals, shouldn’t we be all for it?
“Catching criminals is great,” Ram says. “But privacy is also important. Police could solve more crime if they, for instance, could go rifle through anybody’s home at any time for no reason.” But such searches are illegal, because they violate people’s rights to privacy and security against unreasonable search and seizure.

Some people have suggested this type of search could be limited to solving very serious crimes and cold cases. But such limits have been tried before, Ram notes. Over the past decade, some U.S. states have begun allowing the use of police DNA databases for “familial searches.” Such searches may implicate close relatives of people in the police database as suspects in a crime. “States that embraced that technology initially said, ‘we’re only going to use this for really, really serious crimes.’ ” But then Colorado in 2009 convicted its first suspect with this technique — for “a burglary where someone broke into a car and stole about a dollar and a half in change,” Ram says.

Many people say DNA data should be treated differently than other personal information. “There are things that are unique about genetic data. Most importantly, that it has implications for others,” Grady says. People strive to protect medical information, but medical records reveal things about only an individual. DNA reveals things about relatives, too.

“If I give up my genetic data, you can learn things about people who are related to me that you can’t learn from my cholesterol or my blood pressure, or even my psych history,” Grady says. There should be some safeguards, she adds. “No law enforcement agencies have rules or standards about how they use this kind of information.”

Do any laws protect against this type of search?
Because GEDmatch is a public database, privacy protections that govern private companies probably don’t apply. “If people voluntarily put their data on GEDmatch, they’ve given it away,” Grady says. It’s like they’ve cut their hair and left the hair on the floor. There’s no protection for that.” Other laws governing the privacy of genetic and medical information don’t apply genealogical DNA data deposited in public databases.

But Grady believes that could soon change. “I suspect there will be people entertaining new laws in light of the recent uses.”